The pitch for anti-aging peptides is simple and old: a molecule, injected or swallowed, that quietly slows a process no one has ever stopped in a living human. None of these compounds is an FDA-approved anti-aging drug. Most exist in a gray zone, sold either as compounded prescriptions or as unregulated “research chemicals.” What the actual trial data show, when lined up next to the marketing, is a more complicated and less flattering story than the category usually gets.
Where the evidence actually sits
It helps to sort these compounds by how much real human data backs them, rather than by how confidently they’re marketed. Laid out that way, from strongest evidence to weakest, the picture looks almost inverted from the sales pitch.
NMN sits at the top, evidence-wise, and even that isn’t much. A randomized, placebo-controlled trial in 80 healthy adults over 60 (the strongest human trial in this category) found that NMN raised NAD+ levels and improved performance on a six-minute walk test over 60 days [4]. Researchers were measuring a walking test and a blood marker, not lifespan or biological age. It’s a real, positive result. It’s also small and short.
Humanin, a mitochondrial-derived peptide, produces some of the most interesting biology in the category: it extends lifespan in C. elegans and runs elevated in the blood of centenarians’ children [5]. But that’s an association in humans, not a trial. Nobody has given humanin to people and shown it does anything measurable. The mechanism is intriguing; the human evidence isn’t there yet.
SS-31 (elamipretide) is where the story turns negative. It went through an actual phase 3 trial, MMPOWER-3, published in Neurology in 2023, testing 40 mg a day against placebo in 218 people who had a diagnosed mitochondrial disease. The trial did not meet its primary endpoints; SS-31 failed to outperform placebo on walking distance or fatigue, with only suggestive signals in a genetic subgroup analysis after the fact [1][2]. This was tested in the population most likely to respond, people with an actual mitochondrial disorder, and it still came up short. That result matters more than the marketing does when this same compound is sold to healthy people as a longevity aid.
Thymosin alpha-1 fares no better in its largest trial. It’s the best-established immune peptide in this space, approved in some countries for narrower indications, which made its performance in the TESTS trial notable. Published in the BMJ in 2025, the trial enrolled 1,106 adults with sepsis across 22 centers and found no significant difference in 28-day mortality compared with placebo, a hazard ratio of 0.99 [3]. Sepsis is not aging, and the trial wasn’t testing longevity claims. But if the most established immune peptide in the category fails to beat placebo in the setting where immune support should matter most, “rejuvenates your immune system” is not a claim the evidence currently supports.
Ranked this way, the pattern is consistent: the compound with the strongest data shows a modest, short-term effect on a walking test and a blood marker. The compounds with the boldest reputations have already been tested at scale, in the populations most likely to benefit, and lost to placebo.
The problem underneath the trial data
Even setting the efficacy question aside, researchers and regulators have flagged a more basic issue: what’s actually in the vial.
Most of these compounds circulate as products labeled “for research use only,” sold without independent verification of purity or dose. There’s no regulatory chain behind them, no manufacturing standard, no recall authority, and no accountability if a batch is underdosed, mislabeled, or contaminated. Any certificate of analysis attached to a research-chemical purchase is a document the seller chose to publish, not one an outside body verified.
That gap became an active regulatory concern in 2026. The FDA issued warning letters to a group of research-peptide sellers, stating that a “research use only” label does not exempt a product from oversight when it is marketed for effects in people [6]. In practical terms, the label many buyers treat as reassurance is the exact language regulators said offers no protection.
Long-term safety data is a separate, quieter gap. The trials that exist ran for weeks to months, NMN’s included [4]. The claims made about these compounds are about decades of a person’s life. Between those two timeframes sits an entire category of unknowns: what happens to a healthy person taking an unproven compound, often by injection, often at doses beyond what any published study used, over years rather than weeks. No data exists to answer that question, for most of this category, because the studies haven’t been done. Absence of evidence is not evidence of safety; it’s simply an absence.
There’s a narrower, more concrete risk for tested athletes. Under the WADA 2026 Prohibited List, a range of peptides and growth factors are banned in competitive sport [7]. A “research use only” label provides no exemption, because prohibited status is determined by what a substance is, not by how it was marketed. For anyone competing under anti-doping rules, that distinction can end an eligibility, regardless of what the seller’s website implied.
What connects all of it
Every one of these issues, unverified contents, trials that missed their endpoints, absent long-term data, anti-doping exposure, traces back to the same structural fact: in the typical research-chemical purchase, no clinician is involved at any point. Nobody evaluates the buyer’s health history or medications. Nobody with training assesses whether a specific compound makes sense for a specific person. There’s no prescription, no pharmacy accountable for what was dispensed, and no follow-up if something goes wrong. The buyer is, by default, also the prescriber, the pharmacist, and the safety monitor, a set of roles most people are not equipped to hold at once.
A different model addresses that specific gap, though it’s worth being precise about what it does and doesn’t fix. In a physician-supervised telehealth arrangement, a licensed clinician evaluates the patient, determines whether a compound is appropriate, writes a prescription where warranted, and a licensed pharmacy compounds and dispenses it, with follow-up built in. FormBlends operates this way, routing longevity-adjacent compounds through a clinician and a licensed pharmacy rather than a research-chemical vendor. That structure doesn’t turn an unproven compound into a proven one, and the standard caveat still applies: compounded medications are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness, or quality. What it does add is a qualified person positioned between the buyer and the substance, which is the one safeguard the research-chemical route is missing entirely.
The practical takeaway
The trial data on anti-aging peptides doesn’t describe a scam so much as a mismatch between what’s been shown and what’s being claimed. Some of the underlying biology is genuinely interesting. But the compound with the best human evidence produced a modest, short-term effect on a walking test, and the compounds with the largest reputations have already failed to beat placebo in real phase 3 and BMJ-published trials, in the populations best positioned to show a benefit. Layer on unverified sourcing, no long-term safety data, and anti-doping exposure, and the reasonable position is caution: treat this category as unproven, approach it slowly if at all, and involve a licensed clinician before starting anything in it.
The compounds discussed are early-stage, compounded, or sold for laboratory research use only, and none is an FDA-approved anti-aging or longevity therapy. Talk to a licensed clinician before starting anything in this category.
Questions worth answering
Do anti-aging peptides actually slow aging in humans? Not according to current evidence. None is an FDA-approved anti-aging or longevity drug, and the human trials that exist measure short-term proxies rather than aging itself. The strongest human data in the category, an NMN trial in 80 adults over 60 days, raised NAD+ and improved performance on a walking test, a real but narrow result that says nothing about lifespan or healthspan [4].
Why is “research use only” risky if the label sounds harmless? Because nobody independently verifies that the vial contains what the label claims. There’s no manufacturing chain, no recall authority, and no accountable party if a research-chemical peptide turns out underdosed, mislabeled, or contaminated, a gap that matters more when the product is injected. In 2026 the FDA issued warning letters clarifying that a “research use only” label does not exempt a product marketed for use in people [6].
Which anti-aging peptides have failed in clinical trials? Two of the most widely promoted have missed their endpoints in real trials. SS-31 (elamipretide) failed its phase 3 MMPOWER-3 trial, not beating placebo on walking distance or fatigue among 218 people with a diagnosed mitochondrial disease [1][2]. Thymosin alpha-1, the best-established immune peptide in the category, showed no significant mortality benefit against placebo in the TESTS trial of 1,106 sepsis patients, a hazard ratio of 0.99 [3]. When the strongest candidates underperform in the populations most likely to respond, the anti-aging framing loses its footing.
Is there long-term safety data for people taking these peptides for years? No, and that absence is a risk in itself. Existing trials ran for weeks to months, while the longevity claims made for these compounds are about decades [4]. That leaves a gap where people are taking unproven substances, often by injection and sometimes above studied doses, with no data describing what years of exposure would do. An absence of evidence should not be read as evidence of safety.
Can these peptides cause a failed drug test in sport? Yes. Under the WADA 2026 Prohibited List, a number of peptides and growth factors are banned in competitive sport, and prohibited status is determined by what a substance is, not by how it’s labeled [7]. A “research use only” sticker offers no protection, so a single purchase can jeopardize a tested athlete’s eligibility.
Does going through a clinician and pharmacy actually make this safer than buying online? It doesn’t make an unproven compound proven, but it restores the one safeguard the research-chemical route removes: a qualified person reviewing the decision. In a physician-supervised telehealth model, a licensed clinician evaluates the patient, determines appropriateness, writes a prescription where warranted, and a licensed pharmacy compounds and dispenses the product with follow-up. FormBlends operates on this model, rather than shipping an unverified research chemical directly to a buyer.
Do peptides for anti-aging actually work?
Some do, within limits. Topical peptides like Matrixyl (palmitoyl pentapeptide-4) have modest supporting evidence for collagen support and wrinkle reduction, largely from small, industry-funded trials. Injectable peptides such as BPC-157 or epithalon have larger online followings than peer-reviewed data. Results range from subtle to undetectable, depending on the specific peptide, the dose, and the starting condition of the skin.
Are peptides for anti-aging safe?
Topical peptides used in cosmetics carry a solid safety record, largely because they act on the skin’s surface with minimal absorption. Injectable peptides are a different matter. Most sold online come as unregulated research chemicals, without verified purity, sterility testing, or dosing guidance. Contamination and dosing errors are real possibilities. Safety, in this category, depends heavily on how a compound was manufactured, by whom, and how it’s administered.
What are the best peptides for anti-aging, and how do I know which one to try first?
Among topicals, palmitoyl pentapeptide-4 and copper peptides such as GHK-Cu have the most published support. Among systemic options, growth-hormone secretagogues like sermorelin have the longest clinical track record, though they require a prescription. A topical is the lower-risk starting point. Anyone considering an injectable should start with a conversation with a physician who can order labs and monitor outcomes.
Where should I buy anti-aging peptides, and why does the source matter so much?
Source matters more than nearly any other variable. Research-chemical websites sell peptides intended for laboratory use, not human injection, and independent testing has repeatedly turned up underdosed or contaminated vials. Physician-supervised compounding pharmacies, such as FormBlends, operate under state pharmacy board oversight and USP standards, so what’s on the label reliably matches what’s in the vial. For topicals, established cosmetic brands that list full ingredient concentrations and publish third-party testing remain the safer default.
References
- MMPOWER-3 phase 3 trial of elamipretide (SS-31), 40 mg/day in 218 people with primary mitochondrial myopathy; primary endpoints (six-minute walk test and fatigue) not met. Neurology, 2023. https://www.neurology.org/doi/10.1212/WNL.0000000000207402
- MMPOWER-3 full text confirming participant count, dosing, and the negative primary-endpoint result. Neurology, 2023 (PMC). https://pmc.ncbi.nlm.nih.gov/articles/PMC10382259/
- TESTS phase 3 double-blind, placebo-controlled trial of thymosin alpha-1 (thymalfasin) in 1,106 adults with sepsis across 22 centers; no significant difference in 28-day mortality (HR 0.99). BMJ, 2025.
- NMN randomized, placebo-controlled trial in 80 healthy middle-aged adults; raised NAD+ and improved six-minute walk distance over 60 days. GeroScience, 2023.
- Mitochondrial-derived peptide humanin as a regulator of lifespan and healthspan; lifespan extension in C. elegans, elevated in centenarians’ offspring; human data is association, largely preclinical. Aging, 2020.
- FDA warning letters to research-peptide sellers; “research use only” labeling does not exempt products marketed for human use. FDA, dated March 31, 2026.
- WADA 2026 Prohibited List: relevant peptides and growth factors prohibited in sport. USADA advisory, 2026.
Devin Ochoa is a science journalist covering clinical trial data and drug regulation. This piece was checked against the primary literature cited above.
For general readers, not a prescription. Check in with a qualified clinician before you begin.
